Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Daptomycin · 2 trials · 3 indications
Erythrocyte volume fraction means under certain conditions, after centrifugation pressing, the percentage of erythrocyte volume in the total volume of blood
percentage of patients who were primarily tested as normal ECG at baseline and changed into abnormal ECG at TOC visit in all the patients with normal ECG at baseline
| Arm | Type | Description |
|---|---|---|
| AZ drug | EXPERIMENTAL | Daptomycin |
| Comparator | ACTIVE_COMPARATOR | Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin |
| Name | Type | Description |
|---|---|---|
| Daptomycin | DRUG | 4mg/kg IV ; Q 24 hr (once every 24 hours) |
| Vancomycin | DRUG | Vancomycin - 1g per 12 hrs, for 7-14 days Or switch to Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin: \- 1 g every 6 hours or 2 g every 8 hours |
Inclusion Criteria: * Provision of inform consent * A diagnosis of of complicated skin and skin structure infection known or suspected to be due to Gram-positive bacteria * Diagnosis of bacterial skin and skin structure infection in the presence of some complicating factor, including infections inv...
Daptomycin is a small molecule antibiotic used for skin infections. It is being studied in healthy subjects for pharmacokinetic purposes. The drug is in clinical development for skin diseases, including infectious skin conditions.
Daptomycin is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials for this drug in China.
Daptomycin is in Phase 1 clinical development. It has completed a Phase 1 pharmacokinetic study in healthy Chinese subjects and a Phase 3 registration study in patients with skin infections.
Daptomycin has two completed clinical trials. NCT00772447 is a Phase 3 registration study in patients with skin infections in China, enrolling 265 participants. NCT00858325 is a Phase 1 pharmacokinetic study in healthy Chinese subjects, enrolling 24 participants.
Daptomycin is also known by the brand name Cubicin. The drug is being studied for skin infections and in healthy subjects for pharmacokinetic evaluation.